SCHEMBL190670

SCHEMBL190670

Cc1csc(Nc2cc(Oc3ccc(O)cc3)ccn2)n1

nearest known ligand 0.54

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.54
NPC1 O15118 4/20 0.54
KMT2A Q03164 4/20 0.54
RAB9A P51151 3/20 0.54
POLB P06746 2/20 0.49
GRM5 P41594 2/20 0.48
GCK P35557 10/20 0.47
TRPV4 Q9HBA0 1/20 0.47
GAA P10253 1/20 0.44
KCNN1 Q92952 1/20 0.44
KCNN2 Q9H2S1 1/20 0.44
KCNN3 Q9UGI6 1/20 0.44
SLC2A1 P11166 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL191056 0.89 TRPV4 (0.56) MEN1NPC1KMT2ARAB9AGRM5
SCHEMBL191025 0.88 GCK (0.51) MEN1NPC1KMT2ARAB9APOLB
SCHEMBL190659 0.88 GCK (0.59) MEN1NPC1KMT2ARAB9AGRM5
SCHEMBL191300 0.85 GCK (0.62) GRM5GCKTRPV4KCNN1KCNN2
SCHEMBL190467 0.82 GCK (0.54) MEN1NPC1KMT2APOLBGRM5
SCHEMBL191592 0.82 TRPV4 (0.56) MEN1NPC1KMT2ARAB9AGRM5
SCHEMBL190466 0.82 NPC1 (0.57) MEN1NPC1KMT2ARAB9APOLB
Hydrochloric Acid SCHEMBL191626 0.81 GCK (0.47) MEN1NPC1KMT2ARAB9AGRM5
SCHEMBL190972 0.81 GCK (0.47) MEN1NPC1KMT2ARAB9AGRM5
SCHEMBL191359 0.81 GRM5 (0.48) MEN1NPC1KMT2ARAB9AGRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1986645-B1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC (US) 2012-01-04 EP disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 US disclosed
EP-1986645-A1 GLUCOKINASE ACTIVATORS Array Biopharma, Inc. (US) 2008-11-05 EP disclosed
WO-2007089512-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2007-08-09 WO disclosed
WO-2007089512-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247526-A1 GLUCOKINASE ACTIVATORS GCKR, GCK, GALK1 MEN1 3595/4885NPC1 1862/4885KMT2A 2715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.